...

A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Retatrutide Treatment in the Maintenance of Weight Reduction in Individuals with Obesity (TRIUMPH-6) Protocol Number: Jll-MC-GZQB

After taking an investigational medication (Retatrutide) for weight loss for 80 weeks, to look at the effect on weight when comparing continued Retatrutide to placebo.


Why this Research Matters

A study to evaluate an investigational medication (Retatrutide) in helping people to maintain weight loss in adults with obesity


Who can Participate

Adult

Age of 18 years and older; BMI of 35 or higher; Do not have type 1 or type 2 diabetes; Have not taken any weight loss medication in last 3 months.


Study ID

Protocol Number: 24-2526

Meet the Team

Image of Principal Investigator

Daniel Bessesen, MD

Principal Investigator


Locations

  • Brain Imaging Center (BIC)
  • Anschutz Health and Wellness
  • Outpatient CTRC